BGIM
SRPT icon

Boussard & Gavaudan Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23,173
Closed -$1.72M – 29
2019
Q3 		$1.72M Buy
+23,173
New +$2.74M 0.23% 22

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Boussard & Gavaudan Investment Management's SRPT Position: Q4 2019 in Review

Boussard & Gavaudan Investment Management sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 23,173 shares — an estimated $1.72M sold.

Boussard & Gavaudan Investment Management first reported a position in SRPT in Q3 2019 and held it in 1 quarter. The position peaked at $1.72M in Q3 2019. 390 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

  • Boussard & Gavaudan Investment Management reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 23,173 Sarepta Therapeutics shares in Q4 2019, an estimated $1.72M.
  • Boussard & Gavaudan Investment Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 1 quarter.
  • Boussard & Gavaudan Investment Management's Sarepta Therapeutics position peaked at $1.72M in Q3 2019.
  • 390 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q4 2019, filed 12 Feb 2020.